Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement

Neurological complications after transcatheter aortic valve replacement (TAVR) may be reduced with transcatheter cerebral embolic protection (TCEP). This study evaluated the safety and efficacy of TCEP during TAVR. Nineteen centers randomized 363 patients undergoing TAVR to a safety arm (n = 123), d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of the American College of Cardiology Ročník 69; číslo 4; s. 367
Hlavní autoři: Kapadia, Samir R, Kodali, Susheel, Makkar, Raj, Mehran, Roxana, Lazar, Ronald M, Zivadinov, Robert, Dwyer, Michael G, Jilaihawi, Hasan, Virmani, Renu, Anwaruddin, Saif, Thourani, Vinod H, Nazif, Tamim, Mangner, Norman, Woitek, Felix, Krishnaswamy, Amar, Mick, Stephanie, Chakravarty, Tarun, Nakamura, Mamoo, McCabe, James M, Satler, Lowell, Zajarias, Alan, Szeto, Wilson Y, Svensson, Lars, Alu, Maria C, White, Roseann M, Kraemer, Carlye, Parhizgar, Azin, Leon, Martin B, Linke, Axel
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 31.01.2017
Témata:
Aged
Aged, 80 and over
Aortic Valve - surgery
Cognition
Female
Humans
Intracranial Embolism - prevention & control
Magnetic Resonance Imaging
Male
Safety
Transcatheter Aortic Valve Replacement - methods
Treatment Outcome
transcatheter aortic valve replacement
stroke
cerebral embolic protection
neuroimaging
ISSN:1558-3597, 1558-3597
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Neurological complications after transcatheter aortic valve replacement (TAVR) may be reduced with transcatheter cerebral embolic protection (TCEP). This study evaluated the safety and efficacy of TCEP during TAVR. Nineteen centers randomized 363 patients undergoing TAVR to a safety arm (n = 123), device imaging (n = 121), and control imaging (n = 119). The primary safety endpoint consisted of major adverse cardiac and cerebrovascular events (MACCE) at 30 days, and the primary efficacy endpoint was reduction in new lesion volume in protected brain territories on magnetic resonance imaging scans at 2 to 7 days. Patients underwent neurocognitive assessments, and the debris captured was analyzed. The rate of MACCE (7.3%) was noninferior to the performance goal (18.3%, p  < 0.001) and not statistically different from that of the control group (9.9%; p = 0.41). New lesion volume was 178.0 mm in control subjects and 102.8 mm in the device arm (p = 0.33). A post hoc multivariable analysis identified pre-existing lesion volume and valve type as predictors of new lesion volume. Strokes at 30 days were 9.1% in control subjects and 5.6% in patients with devices (p = 0.25) Neurocognitive function was similar in control subjects and patients with devices, but there was a correlation between lesion volume and neurocognitive decline (p = 0.0022). Debris found within filters in 99% of patients included thrombus, calcification, valve tissue, artery wall, and foreign material. TCEP was safe, captured embolic debris in 99% of patients, and did not change neurocognitive function. Reduction in new lesion volume on magnetic resonance scans was not statistically significant. (Cerebral Protection in Transcatheter Aortic Valve Replacement [SENTINEL]; NCT02214277).
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1558-3597
1558-3597
DOI:10.1016/j.jacc.2016.10.023